Thursday, November 04, 2021 1:44:01 PM
A couple of things: First, the Lancet article and draft guidelines were recently published...the expression of those thoughts, in those documents, appears to be something that NWBO was waiting on, based on some of the summaries of conversations with DI that have been posted here. If the FDA had already accepted the endpoint changes back in October, why would NWBO care about convincing the public that historical controls should be used for its trial? Why is LL advocating for the use of historical controls during her presentations? If the FDA was on board last October, why not release TLD and include a statement that the FDA had accepted the endpoint changes?
Second, the fact that those documents exist does NOT mean that the FDA has accepted that line of thinking for NWBO's request to change endpoints, or at least that they have already accepted it.
Third, with respect to Orbis, if NWBO is counting on Sawston and its 500 vaccines per year, then we are in big trouble (with respect to Orbis only...I'm all for the 500 vaccines and don't mean to downplay the significance of being able to achieve this). 500 vaccines per year doesn't move the needle on anticipated demand. They need a new manufacturing agreement with CRL or they can't satisfy the capacity and rapid manufacturing demands of Orbis, as I understand them. Hopefully a new CRL manufacturing agreement is part of the barrage of PRs LG has alluded to after the release of TLD.
Lastly, if you think datalock means that the new endpoints were accepted, great. I don't know that this is the case. But, if the datalock means with 100% certainty that the new endpoints were accepted, then I don't see why the company needed to wait for the new historical control guidance to come out in the late summer or for a journal article explaining the full trial results.
Look, I don't have any idea what is going on, none of us do. But I do know that what is happening here is unprecedented. There is a reason that no pre-revenue biotech has EVER released trial data in this way. Is it because the results are so good that they need over 13 months to tell us about? I don't know...I certainly hope that is the case.
Second, the fact that those documents exist does NOT mean that the FDA has accepted that line of thinking for NWBO's request to change endpoints, or at least that they have already accepted it.
Third, with respect to Orbis, if NWBO is counting on Sawston and its 500 vaccines per year, then we are in big trouble (with respect to Orbis only...I'm all for the 500 vaccines and don't mean to downplay the significance of being able to achieve this). 500 vaccines per year doesn't move the needle on anticipated demand. They need a new manufacturing agreement with CRL or they can't satisfy the capacity and rapid manufacturing demands of Orbis, as I understand them. Hopefully a new CRL manufacturing agreement is part of the barrage of PRs LG has alluded to after the release of TLD.
Lastly, if you think datalock means that the new endpoints were accepted, great. I don't know that this is the case. But, if the datalock means with 100% certainty that the new endpoints were accepted, then I don't see why the company needed to wait for the new historical control guidance to come out in the late summer or for a journal article explaining the full trial results.
Look, I don't have any idea what is going on, none of us do. But I do know that what is happening here is unprecedented. There is a reason that no pre-revenue biotech has EVER released trial data in this way. Is it because the results are so good that they need over 13 months to tell us about? I don't know...I certainly hope that is the case.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
